StudyID,Drug_Name,Prot_No,NCT_No,EUCT_No,Other_No,Inv_Prod,Study_Phase,Start_Date,Termin_Date,Complet_Date,Data_Cutoff_Date,Name_PI,Sponsor,GCP_Compliance,Study_First_Posted_Date,Route_Admin,Treat_Duration,Add_On_Treat,Arm_Description,Adherence_Treat,MRCT,No_Center,No_Center_NA,No_Center_AP,No_Center_WEU,No_Center_EEU,No_Center_AF,Enroll_Duration_Plan,FU_Duration_Plan,Central_Lab,Run_in,DMC
NCT00585195,PF-02341066; Rifampin; Itraconazole,A8081001,NCT00585195,,PROFILE 1001,PF-02341066; Rifampin; Itraconazole,Phase 1,"April 19, 2006",,"January 19, 2022",,,Pfizer,,"January 3, 2008",oral,28 days (or 21 days depending on the cohort),yes,,,Yes,28,23,5,0,0,0,,,,,No
